England's MS risk sharing scheme fails, researchers find - update
This article was originally published in SRA
A risk sharing scheme set up in 2002 by the Department of Health in England and Wales to establish the cost-effectiveness of multiple sclerosis drugs is a “costly failure” for the National Health Service and should not be continued, claim researchers in articles published in the BMJ1.
You may also be interested in...
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.